



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/729,475	12/05/2003	Steve Pakola	113476.122US1	3082
23483	7590	09/29/2008		
WILMERHALE/BOSTON				
60 STATE STREET				
BOSTON, MA 02109				
EXAMINER				
KIM, TAEYOUN				
ART UNIT		PAPER NUMBER		
1651				
NOTIFICATION DATE		DELIVERY MODE		
09/29/2008		ELECTRONIC		

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

michael.mathewson@wilmerhale.com

teresa.carvalho@wilmerhale.com

sharon.mathews@wilmerhale.com

### Interview Summary

**Application No.**

10/729,475

**Applicant(s)**

PAKOLA ET AL.

**Examiner**

TAEYOON KIM

**Art Unit**

1651

All participants (applicant, applicant's representative, PTO personnel):

(1) Taeyoon Kim/Blaine Lankford.(3) Franky Terras.(2) Steve Pacola.(4) Donna Meuth.

Date of Interview: 17 September 2008.

Type: a) ☐ Telephonic b) ☐ Video Conference

c) ☒ Personal (copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☒ Yes e) ☐ No.

If Yes, brief description: power point presentation on clinical trials using the invention.

Claim(s) discussed: ALL.

Identification of prior art discussed: Trese et al.

Agreement with respect to the claims f) ☐ was reached. g) ☒ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Applicant presented latest findings (unexpected results) on clinical studies using the invention (i.e. microplasmin) and discussed differences in comparison with the prior art (i.e. plasmin). Applicant was advised to argue the 103 rejections based on the unexpected results from the clinical studies.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

/Taeyoon Kim/  
Examiner, Art Unit 1651